Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

joint care composition

A composition and dry matter technology, applied in the prevention or treatment of osteoarthritis, the field of composition for the prevention or treatment of osteoarthritis, capable of solving problems related to adverse reactions

Active Publication Date: 2020-12-01
MARS INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most commonly used are NSAIDs, but these drugs are associated with adverse effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • joint care composition
  • joint care composition
  • joint care composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1: Individual Screening of Compounds

[0068] Experiments were performed to evaluate the effect of several compounds on primary cultures of bovine chondrocytes in which inflammatory and catabolic processes were induced by interleukin-1β to mimic the effects of arthritic chondrocytes.

[0069] The table below details the biomarkers determined throughout the experiments to show the effect of the compounds on the three metabolic pathways on chondrocytes.

[0070] Table 3: Biomarkers detected

[0071]

[0072] Primary culture of monolayer bovine chondrocytes

[0073]Normal bovine articular cartilage was obtained from the metacarpal-phalangeal joint of shortly after mortem bulls aged 1 to 2 years. Full-depth articular cartilage was excised and immersed in supplemented with N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES) 10mM, penicillin (100U / ml) and chain Mycin (0.1 mg / ml) (both from Lonza (Lonza) Verviers, Belgium) Dulbecco's Modified Eagl...

Embodiment 2

[0092] Example 2: Dose Response

[0093] Carry out according to the method for embodiment 1. According to the molecular weight, 4 different concentrations were tested: 0.5 μg / ml, 2.5 μg / ml, 12.5 μg / ml and 62.5 μg / ml to cover the corresponding 10 -5 M concentration range.

[0094] The results showed that, for each compound, the concentration that gave the best effect and gave no toxic effects was 12.5 μg / ml. This is why a concentration of 12.5 μg / ml was used in combination with each other to test the compounds.

Embodiment 3

[0095] Example 3: Specific combinations and synergistic effects of test compounds

[0096] The method of Example 1 was carried out.

[0097] compound supplementation

[0098] When the cells reached confluence, the medium was removed and replaced with fresh medium (supplemented with 1% fetal bovine serum, 10 mM HEPES, 100 U / ml penicillin, 0.1 mg / ml streptomycin, 2 mM glutamine, and 20 μg / ml proline). DMEM without phenol red and containing only 1 g / L glucose) was replaced by fresh medium containing some compounds (12.5 μg / ml each) and with or without recombinant porcine IL-1β (10 -11 M) (RD Systems, Abingdon, UK). Three compounds were tested, turmeric extract (Naturex, Avignon, France), hydrolyzed collagen (Galida, Eberbach, Germany) and green tea extract (Naturex, Avignon Ong, France). Turmeric extract was prepared as a 12.5 mg / ml solution in tetrahydrofuran (Merck, Leuven, Belgium) and further diluted 1000-fold in cell culture medium. Hydrolyzed collagen and green tea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition for preventing or treating osteoarthritis, the composition comprising curcumin and green tea polyphenols, or a combination with glycine, proline and hydroxyproline. The present invention also relates to a method for preventing or treating osteoarthritis in a mammal, said method comprising administering a composition to said mammal, said composition comprising curcumin and green tea polyphenols, or combining them with Combination of Glycine, Proline and Hydroxyproline.

Description

technical field [0001] The present invention relates to a composition for preventing or treating osteoarthritis, which comprises curcuminoid and green tea polyphenols, or a combination of glycine, proline and hydroxyproline. The present invention also relates to a method for preventing or treating osteoarthritis in a mammal, the method comprising administering a composition to the mammal, the composition comprising curcumin and green tea polyphenols, or glycine , a combination of proline and hydroxyproline. Background technique [0002] Cartilage degeneration can be caused by several reasons, such as repetitive motion, instability of the joint, etc., which may lead to inflammation of the joint. While a greater proportion of humans with arthritis have rheumatoid arthritis, the majority of arthritis that occurs in companion animals is osteoarthritis. [0003] Today, no cure for osteoarthritis exists, and drug treatments are limited to relieving symptoms. The most commonly u...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/01
CPCA61K38/014A61K31/12A61K31/198A61K31/401A23V2002/00A23L33/105A23L33/175A61K38/39A61K36/82A61P19/02A61P19/08A61P43/00A61K2300/00A23V2200/30A23V2250/0622A23V2250/064A23V2250/2112A23V2250/214A23V2250/5422A61K31/05A61K31/353A61K45/06
Inventor S·塞里西耶F·孔布莱恩Y·昂罗廷
Owner MARS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com